Neos Therapeutics (NASDAQ:NEOS) Lifted to “Hold” at ValuEngine

ValuEngine upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a sell rating to a hold rating in a research report released on Thursday morning, ValuEngine reports.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Neos Therapeutics from a buy rating to a hold rating in a research report on Friday, July 26th. Cantor Fitzgerald dropped their price objective on shares of Neos Therapeutics from $20.00 to $10.00 and set an overweight rating for the company in a research report on Wednesday, June 12th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $6.88.

Shares of Neos Therapeutics stock traded down $0.03 during trading hours on Thursday, hitting $1.33. The company’s stock had a trading volume of 92,681 shares, compared to its average volume of 179,626. Neos Therapeutics has a 1-year low of $1.13 and a 1-year high of $6.30. The firm has a fifty day moving average price of $1.35. The company has a quick ratio of 1.27, a current ratio of 1.49 and a debt-to-equity ratio of 41.70.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $14.63 million during the quarter, compared to analyst estimates of $14.20 million. On average, research analysts expect that Neos Therapeutics will post -0.61 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alambic Investment Management L.P. acquired a new position in Neos Therapeutics during the 1st quarter valued at about $32,000. Rhumbline Advisers lifted its position in Neos Therapeutics by 43.5% during the 1st quarter. Rhumbline Advisers now owns 53,730 shares of the company’s stock valued at $140,000 after purchasing an additional 16,288 shares during the period. BNP Paribas Arbitrage SA lifted its position in Neos Therapeutics by 1,749.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock valued at $26,000 after purchasing an additional 9,552 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new position in Neos Therapeutics during the 1st quarter valued at about $63,000. Finally, Virtu Financial LLC acquired a new position in Neos Therapeutics during the 1st quarter valued at about $131,000. 54.87% of the stock is owned by institutional investors and hedge funds.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: Capital Gains Distribution

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.